Corvus Pharmaceuticals, Inc. 10-K Cybersecurity GRC - 2024-03-19

Page last updated on July 16, 2024

Corvus Pharmaceuticals, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-19 16:02:50 EDT.

Filings

10-K filed on 2024-03-19

Corvus Pharmaceuticals, Inc. filed a 10-K at 2024-03-19 16:02:50 EDT
Accession Number: 0001558370-24-003567

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C. Cybersecurity Cybersecurity Risk Management and Strategy We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. Our cybersecurity risk management program includes: ● risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment; ● a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents; ● the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls; ● cybersecurity awareness training of our employees, incident response personnel, and senior management; and ● a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents. We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. Cybersecurity Governance Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (“Committee”) oversight of cybersecurity and other information technology risks. The Committee oversees management’s implementation of our cybersecurity risk management program. The Committee has received reports from management on our cybersecurity risks and will receive such reports on a periodic basis going forward. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. The Committee reports to the full Board regarding its activities which include those related to cybersecurity. As part of our management team, Leiv Lea, our Chief Financial Officer, who has over fifteen years of experience overseeing information technology systems for public companies, is responsible for assessing and managing our material risks from cybersecurity threats. Mr. Lea has primary responsibility for our overall cybersecurity risk management program and supervises our retained external information technology and cybersecurity consultants. Mr. Lea supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from security personnel and alerts and reports produced by security tools deployed in the Company’s information technology environment.


Company Information

NameCorvus Pharmaceuticals, Inc.
CIK0001626971
SIC DescriptionPharmaceutical Preparations
TickerCRVS - Nasdaq
Website
CategoryNon-accelerated filer
Smaller reporting company
Fiscal Year EndDecember 30